Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis
CONCLUSIONS: Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.PMID:37889184 | PMC:PMC10612456 | DOI:10.1177/14799731231210559 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - October 27, 2023 Category: Respiratory Medicine Authors: Fengjia Chen Zhimin Zeng Xinyan Huang Yangli Liu Source Type: research
Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis
CONCLUSIONS: Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.PMID:37889184 | PMC:PMC10612456 | DOI:10.1177/14799731231210559 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - October 27, 2023 Category: Respiratory Medicine Authors: Fengjia Chen Zhimin Zeng Xinyan Huang Yangli Liu Source Type: research
Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis
CONCLUSIONS: Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.PMID:37889184 | DOI:10.1177/14799731231210559 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - October 27, 2023 Category: Respiratory Medicine Authors: Fengjia Chen Zhimin Zeng Xinyan Huang Yangli Liu Source Type: research
Simultaneous evaluation of the fractional exhaled nitric oxide and blood eosinophil count of T2-high endotype in patients with non-cystic fibrosis bronchiectasis
CONCLUSIONS: Simultaneous evaluation of FeNO and BEC proposed different endotypes of bronchiectasis established that patients with low BEC and high FeNO had better lung function, fewer affected lobes, lower dyspnea prevalence, and less disease severity. This result will contribute to a more comprehensive assessment of the disease severity and lead to more precise treatment of T2 inflammation in bronchiectasis patients.PMID:37889184 | DOI:10.1177/14799731231210559 (Source: Chronic Respiratory Disease)
Source: Chronic Respiratory Disease - October 27, 2023 Category: Respiratory Medicine Authors: Fengjia Chen Zhimin Zeng Xinyan Huang Yangli Liu Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
Chron Respir Dis. 2023 Jan-Dec;20:14799731231202257. doi: 10.1177/14799731231202257.ABSTRACTThis review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients wit...
Source: Chronic Respiratory Disease - October 6, 2023 Category: Respiratory Medicine Authors: Edward M Kerwin Paul W Jones Leif H Bjermer Fran çois Maltais Isabelle H Boucot Ian P Naya David A Lipson Chris Compton Lee Tombs Claus F Vogelmeier Source Type: research
